Advertisement

Is Long-Term Antithyroid Drug Therapy for Graves’ Disease Cost-Effective?

  • Joel I. Hamburger

Abstract

Antithyroid drugs (ATD) have been employed for the treatment of hyperthyroidism (principally Graves’ disease) since the 1940s. ATD treatment will be followed by remission in the hyperthyroidism for some patients. Initially good results were claimed for 50–70% of patients.1,2 Recently success has been achieved in 15–30%,3–5 excepting the unique report of Slingerland and Burrows6 in which a 76% remission rate is claimed after prolonged treatment. Favorable candidates for ATD are young, have small goiters or goiters which regress during treatment, and have mild hyperthyroidism of short duration.1,5,7,8

Keywords

Radioactive Iodine Veteran Administration Sustained Remission Hyperthyroid Patient Subtotal Thyroidectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Solomon DH, Beck JC, Vandeaan WP, Astwood EB: Prognosis of hyperthyroidism treated by antithyroid drugs. JAMA 152:201, 1953Google Scholar
  2. 2.
    Hershman JM, Givens JR, Cassidy CE, Astwood EB: Long-term outcome of hyperthyroidism treated with antithyroid drugs. J Clin Endocrinol Metab 26:803, 1966PubMedCrossRefGoogle Scholar
  3. 3.
    Wartofsky L: Low remission after therapy for Graves’ disease. JAMA 226:1083, 1973.PubMedCrossRefGoogle Scholar
  4. 4.
    Greer MA, Kammer H, Bouma DJ: Short-term antithyroid drug therapy for the thyrotoxicosis of Graves’s disease. N Engl J Med 297:173, 1977PubMedCrossRefGoogle Scholar
  5. 5.
    Reynolds LR, Kotchen TA: Antithyroid drugs and radioactive iodine: Fifteen years’ experience with Graves’ disease. Arch Intern Med 139:651, 1979PubMedCrossRefGoogle Scholar
  6. 6.
    Slingerland DW, Burrows BA: Long-term antithyroid treatment in hyperthyroidism. JAMA 242:2408, 1979PubMedCrossRefGoogle Scholar
  7. 7.
    Chevalley J, McGavack TH, Kenigsberg S, Pearson S: A four-year study of the treatment of hyperthyroidism with methimazole. J Clin Endocrinol Metab 14:948, 1954PubMedCrossRefGoogle Scholar
  8. 8.
    Wool MS: The investigation and treatment of hyperthyroidism. Surg Clin North Am 50:545, 1970PubMedGoogle Scholar
  9. 9.
    Howard JE: Treatment of thyrotoxicosis. JAMA 202:146, 1967CrossRefGoogle Scholar
  10. 10.
    Nikolai TF, Brosseau J, Kettrick MA, Roberts R, Beltaos E: Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 140:478, 1980PubMedCrossRefGoogle Scholar
  11. 11.
    Rosove MH: Agranulocytosis and antithyroid drugs. West J Med 126:339, 1977PubMedGoogle Scholar
  12. 12.
    Vaidya VA, Bongiovanni AM, Parks JS, Tenore A, Kirkland RT: Twenty-two years’ experience in the medical management of juvenile thyrotoxicosis. Pediatrics 54:565, 1974PubMedGoogle Scholar
  13. 13.
    Irvine WJ, Toft AD, Lidgard GP, Gray RS, Seth J, Cameron EHD: Spectrum of thyroid function in patients remaining in remission after antithyroid drug therapy for thyrotoxicosis. Lancet 2:179, 1975Google Scholar
  14. 14.
    Wood LC, Peterson M, Ingbar SH: Hypothyroidism as a late sequela in patients with Graves’ disease treated with antithyroid agents. J Clin Invest 64:1429, 1979PubMedCrossRefGoogle Scholar
  15. 15.
    Tamai H, Nakagawa T, Fukino O, Ohsako N, Shinzato R, Suematsu H, Kuma K, Matsuzuka F, Nagataki S: Thionamide therapy in Graves’ disease: Relation of relapse rate to duration of therapy. Ann Intern Med 92:488, 1980PubMedGoogle Scholar
  16. 16.
    Burr WA, Fitzgerald MG, Hoffenberg R: Relapse after short-term antithyroid therapy of Graves’ disease. N Engl J Med 297:173, 1977CrossRefGoogle Scholar
  17. 17.
    McLarty DG, Alexander WD, Harden RMcG, Clark DH: Results of treatment of thyrotoxicosis following relapse after antithyroid drug therapy. Br Med J 3:203,1969PubMedCrossRefGoogle Scholar
  18. 18.
    Greer MA: Antithyroid drugs in the treatment of thyrotoxicosis. Thyroid Today 3:1, 1980Google Scholar
  19. 19.
    Bowers RF: Hyperthyroidism: comparative results of medical (131I) and surgical therapy. Ann Surg 162:478, 1965PubMedCrossRefGoogle Scholar
  20. 20.
    Hamburger JI, Garcia M, Meier DA, Stoffer SS, Taylor CI: The Thyroid Gland. A Book for Thyroid Patients. Southfield, Mich., 1979 (private publication)Google Scholar
  21. 21.
    Utiger RD: Treatment of Graves’ disease. N Engl J Med 298:681, 682, 1978Google Scholar
  22. 22.
    Foster RS Jr: Morbidity and mortality after thyroidectomy. Surg Gynecol Obstet 146:423, 1978PubMedGoogle Scholar
  23. 23.
    Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ: Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 17:460, 1976PubMedGoogle Scholar
  24. 24.
    Robertson JS, Gorman CA: Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. J Nucl Med 17:826, 1976PubMedGoogle Scholar
  25. 25.
    Freitas JE, Swanson DP, Gross MD, Sisson JC: Iodine-131: Optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med 20:847, 1979PubMedGoogle Scholar
  26. 26.
    Safa AM, Schumacher OP, Rodriguez-Antunez A: Long-term followup results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 292:167, 1975PubMedCrossRefGoogle Scholar
  27. 27.
    Stanbury JB, Chapman EM: Nonoperative management of hyperthyroidism. In Varco RL, Delaney JP (eds): Controversy in Surgery. Philadelphia, Saunders, 1976, pp 555–564Google Scholar
  28. 28.
    Eisen MJ: Fulminant hepatitis during treatment with propylthiouracil. N Engl J Med 249:814, 1953PubMedCrossRefGoogle Scholar
  29. 29.
    Mihas AA, Holley P, Koff RS, Hirschowitz BI: Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 70:770, 1976PubMedGoogle Scholar
  30. 30.
    Colwell AR Jr, Santo D, Land SG: Propylthiouracil-induced agranulocytosis, toxic hepatitis, and death. JAMA 148:639, 1952Google Scholar
  31. 31.
    Weiss M, Hassin D, Bank H: Propylthiouracil-induced hepatic damage. Arch Intern Med 140:1184, 1980PubMedCrossRefGoogle Scholar
  32. 32.
    Chapman EM: The treatment of hyperthyroidism. N Engl J Med 265:744; 844; 948; 1961CrossRefGoogle Scholar
  33. 33.
    Kidd A, Okita N, Row VV, Volpé R: Immunologic aspects of Graves’ and Hashimoto’s diseases. Metabolism 29:80, 1980PubMedCrossRefGoogle Scholar
  34. 34.
    McGregor AM, Peterson MM, McLachlan SM, Rooke P, Smith BR, Hall R: Carbimazole and the autoimmune response in Graves’ disease. N Engl J Med 303:302, 1980PubMedCrossRefGoogle Scholar
  35. 35.
    Greer MA, Deeney JM: Antithyroid activity elicited by the ingestion of pure progoitrin, a naturally occurring thioglycoside of the turnip family. J Clin Invest 38:1465, 1959PubMedCrossRefGoogle Scholar
  36. 36.
    Greer MA, Meihoff W, Studer H: Treatment of hyperthyroidism with a single daily dose of propylthiouracil. N Engl J Med 272:888, 1965PubMedCrossRefGoogle Scholar
  37. 37.
    Volpé R: The role of autoimmunity in hypoendocrine and hyperendocrine function. Ann Intern Med 87:86, 1977PubMedGoogle Scholar
  38. 38.
    Hallengreen B, Forsgen A, Melander A: Effect of antithyroid drugs on lymphocyte function in vitro. J Clin Endocrinol Metab 51:298, 1980CrossRefGoogle Scholar
  39. 39.
    Wall JR, Manwar GL, Greenwood DM, Walters BA: The in vitro suppression of lectin-induced 3H-thymidine incorporation into DNA of peripheral blood lymphocytes after the addition of propylthiouracil. J Clin Endocrinol Metab 43:1406, 1976PubMedCrossRefGoogle Scholar
  40. 40.
    Alexander WD, Marty DG, Horton P, Pharmakiotes AD: Sequential assessment during drug treatment of thyrotoxicosis. Clin Endocrinol 2:43, 1973CrossRefGoogle Scholar
  41. 41.
    Hackenberg K, Reinwein D: Kontrollierte Hyperthyreose-therapie. Ergeb Inn Med Kinderheilkd 37:20, 1975Google Scholar
  42. 42.
    Romaldini JH, Brombert N, Rodrigues HF, Tanaka LM, Bevilacqua EM, Werner MC, Reis LCF: Management of hyperthyroidism with high dosages of antithyroid drugs (ATD) associated with triiodothyronine (T3). In Stockigt J, Nagataki S (eds): Thyroid Research VIII. Proceedings of the 8th International Thyroid Conference, Sidney, Australia. Canberra, Griffin Press, Australian Academy of Sciences, 1980, p 633Google Scholar
  43. 43.
    Davies TF, Yeo PPB, Evered DC, Smith BR, Clark F, Hall R: Value of thyroid-stimulating antibody determinations in predicting short-term thyrotoxic relapse in Graves’ disease. Lancet 1:1181, 1977PubMedCrossRefGoogle Scholar
  44. 44.
    Schleusener H, Finke R, Kotulla P, Wenzel KW, Meinhold H, Roedler HD: Determination of thyroid-stimulating immunoglobulins (TSI) during the course of Graves’ disease. A reliable indicator for remission and persistence of this disease? J Endocrinol Invest 1:155, 1978PubMedGoogle Scholar
  45. 45.
    Fenzi G, Hashizume K, Rodebush CP, Degroot LJ: Changes in thyroid-stimulating immunoglobulins during antithyroid therapy. J Clin Endocrinol Metab 48:572, 1979PubMedCrossRefGoogle Scholar
  46. 46.
    Teng, CS, Yeung RTT: Changes in thyroid-stimulating antibody activity in Graves’ disease treated with antithyroid drugs and its relationship to relapse: a prospective study. J Clin Endocrinol Metab 50:144, 1980PubMedCrossRefGoogle Scholar
  47. 47.
    Kuzuya N, Chiu SCH, Ikeda H, Uchimura H, Ito K, Nagataki S: Correlation between thyroid stimulators and 3, 5, 3’-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities. J Clin Endocrinol Metab 48:706, 1979PubMedCrossRefGoogle Scholar
  48. 48.
    Zakarija M, Menzie JM: Clinical significance of assay of thyroid-stimulating antibody in Graves’ disease. Ann Intern Med 93:28, 1980PubMedGoogle Scholar
  49. 49.
    McKenzie JM, Zakarija M: Factors and concepts in autoimmune stimulation of the thyroid: autoimmunity in thyroid diseases. In Klein E, Horster FA, Beysel D (eds): Proceedings of the International Thyroid Symposium in Munich, October 1978. Stuttgart, Schattauer Verlag, 1979, p 107Google Scholar
  50. 50.
    Endo K, Kasagi K, Konishi J, Ikekubo K, Okuno T, Takeda Y, Mori T, Torizuka K: Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 46:734, 1978PubMedCrossRefGoogle Scholar
  51. 51.
    Ozawa Y, Maciel RMB, Chopra I J, Solomon DH, Beall GN: Relationship among immunoglobulin markers in Graves’ disease. J Endocrinol Metab 48:381, 1979CrossRefGoogle Scholar
  52. 52.
    Sugenoya A, Kidd A, Row VV, Volpe R: Correlation between thyrotropin-displacing activity and human thyroid-stimulating activity by immunoglobulins from patients with Graves’ disease and other thyroid disorders. J Clin Endocrinol Metab 48:398, 1979PubMedCrossRefGoogle Scholar
  53. 53.
    Finke R, Kotulla P, Wenzel B, Bogner U, Meinhold H, Schleusener H: Klinische Bedeutung der Bestimmung von schilddresenstimulierenden Antikoerpern (TDA). Dtsch Med Wochenschr (in press)Google Scholar
  54. 54.
    Grumet FC, Payne RO, Konishi J, Kriss JP: HL-A antigens as markers for disease susceptibility and autoimmunity in Graves’ disease. J Clin Endocrinol Metab 39:1115, 1974PubMedCrossRefGoogle Scholar
  55. 55.
    Whittingham S, Morris PJ, Martin FIR: HL-A8: a genetic link with thyrotoxicosis. Tissue Antigens 6:23, 1975PubMedCrossRefGoogle Scholar
  56. 56.
    Thorsby E, Segaard E, Solem JH, Kornstad L: The frequency of major histocompatibility antigens (SD and LD) in thyrotoxicosis. Tissue Antigens 6:54, 1975CrossRefGoogle Scholar
  57. 57.
    Bech K, Lumholtz B, Nerup J, Thomsen M, Platz P, Ryder L, Svejgaard A, Siersboek-Nielsen K, Hansen JM, Larsen JH: HLA antigens in Graves’ disease. Acta Endocrinol 86:510, 1977PubMedGoogle Scholar
  58. 58.
    Farid NR, Barnard JM, Marshall WH, Woolfrey I, O’Driscoll RF: Thyroid autoimmune disease in a large Newfoundland family: the influence of HLA. J Clin Endocrinol Metab 45:1166, 1977CrossRefGoogle Scholar
  59. 59.
    Schernthaner G, Schleusener H, Finke R, Kotulla P, Ludwig H, Mayr WR: Thyroid stimulating immunoglobulins in HLA-typed patients with ophthalmic Graves’ disease, thyrotoxicosis, and Hashimoto’s thyroiditis. Acta Endocrinol 87 (Suppl. 215):76, 1978Google Scholar
  60. 60.
    Irvine WJ, Gray RS, Morris PJ, Ting A: Correlation of HLA and thyroid antibodies with clinical course of thyrotoxicosis treated with antithyroid drugs. Lancet 2:898, 1977PubMedCrossRefGoogle Scholar
  61. 61.
    McGregor AM, Smith BR, Hall R, Petersen MM, Miller M, Dewar PJ: Prediction of relapse in hyperthyroid Graves’ disease. Lancet 1:1101, 1980PubMedCrossRefGoogle Scholar
  62. 62.
    Schleusener H, Schernthaner G, Mayr WR, Kotulla P, Bogner U, Wenzel B, Koopenhagen K: Evaluation of HLA-typing (A, B, C, DR) and immunological assessment in predicting the long-term course of Graves’ disease. In Stockigt J, Nagataki S (eds): Thyroid Research VIII. Proceedings of the 8th International Thyroid Conference. Canberra, Griffin Press, Australian Academy of Sciences, 1980, p 617Google Scholar
  63. 63.
    Schernthaner G, Schleusener H, Kotulla P, Finke R, Wenzel B, Mayr WR: Prediction of relapse or long-term remission in hyperthyroid Graves’ disease. Lancet 2:373, 1980PubMedCrossRefGoogle Scholar
  64. 64.
    Schleusener H, Schernthaner G, Mayr WR, Kotulla P, Bogner U, Wenzel B, Finke R, Meinhold H, Koppenhagen K: Toxic scintigraphically diffuse goiter—two genetically different entities. Evaluation of the assessment of HLA-DR in the distinction of two disorders, (in preparation)Google Scholar
  65. 65.
    Schleusener H, Kotulla P, Fink R, Sorje H, Meinhold H, Adlkofer F, Wenzel KW: Relationship between thyroid status and Graves’ disease-specific immunoglobulins. J Clin Endocrinol Metab 47:379, 1978PubMedCrossRefGoogle Scholar
  66. 66.
    Fenzi GF, Pinchera A, Bartalena L, Monzani F, Macchia E, Mammoli C, Baschieri L: Thyroid plasma membrane antigens and TSH receptor. In Stockigt J, Nagataki S (eds): Thyroid Research VIII. Proceedings of the 8th International Thyroid Congress. Canberra, Griffin Press, Australian Academy of Sciences, 1980, p 703Google Scholar
  67. 67.
    Gemsenjager E, Staub JJ, Girard J, Hetty P: Preclinical hyperthyroidism in multinodular goiter. J Clin Endocrinol Metab 43:810, 1976PubMedCrossRefGoogle Scholar
  68. 68.
    Dige-Petersen H, Hummer L: Serum-thyrotropin concentrations under basal conditions and after stimulation with thyrotropin-releasing hormone in idiopathic nontoxic goiter. J Clin Endocrinol Metab 44:1115, 1977PubMedCrossRefGoogle Scholar
  69. 69.
    Emrich D, Bàhre M: Autonomy in euthyroid goiter: maladaption to iodine deficiency. Clin Endocrinol 8:257, 1978CrossRefGoogle Scholar
  70. 70.
    Studer H, Hunziker HR, Ruchti C: Morphologic and functional substrate of thyrotoxicosis caused by nodular goiters. Am J Med 65:227, 1978PubMedCrossRefGoogle Scholar
  71. 71.
    Miller JM: Plummer’s disease: an overview. J Mol Med 4:3, 1980Google Scholar
  72. 72.
    Elte JWF, Wiarda KS, Bussemaker JK, Froelich M, Bolk JH, Vander-Heide D, Haak A: Autonomously functioning euthyroid multinodular goiter. J Mol Med 4:39, 1980Google Scholar
  73. 73.
    Joseph K, Mahlstedt J, Welcke U: Autonomously functioning thyroid tissue (AFTT) during iodine prophylaxis. J Mol Med 4:87, 1980Google Scholar
  74. 74.
    Joseph K, Mahlstedt J, Gonnermann R, Herbert K, Welcke U: Early recognition and evaluation of the risk of hyperthyroidism in thyroid autonomy in an endemic goiter area. J Mol Med 4:21, 1980Google Scholar
  75. 75.
    Schleusener H, Joseph K, Mahlstedt J, Kotulla P, Bogner U, Wenzel B, Meinhold H: Differences between immunogenic toxic diffuse goiters (Graves’ disease) and goiter with disseminated autonomy: preliminary results. J Mol Med 4:129, 1980Google Scholar
  76. 76.
    Schleusener H, Joseph K, Mahlstedt J, Kotulla P, Bogner U, Wenzel B, Meinhold H: Evaluation of thyroid autoantibodies in distinguishing between Graves’ disease and disseminated thyroid autonomy. Acta Endocrinol 94 (Suppl. 234):23, 1980Google Scholar
  77. 77.
    Slingerland DW, Dell ES, Burrows BA: The spectrum of thyroid function after radioiodine treatment. In Fellinger K, Hofer R (eds): Further Advances in Thyroid Research. Vienna, Gistel and Cie, 1971, pp 993–1033Google Scholar
  78. 78.
    Burrows BA: Goiter: diagnosis and treatment. Med Clin North Am:1291, 1958Google Scholar
  79. 79.
    Sterling K, Hoffenberg R: Beta blocking agents and antithyroid drugs as adjuncts to radioiodine therapy. Semin Nucl Med 1:422, 1971PubMedCrossRefGoogle Scholar
  80. 80.
    Sterling K: Diagnosis and Treatment of Thyroid Diseases. Cleveland, CRC Press, 1975Google Scholar
  81. 81.
    Reilly PC Jr, Reilly MC: The cost of outpatient physicians’ services at a Veterans Administration hospital. Ann Intern Med 93:128, 1980PubMedGoogle Scholar
  82. 82.
    Jameson JH, Baker CR: Costs in Veterans Administration hospitals. Ann Intern Med 93:782, 1980PubMedGoogle Scholar
  83. 83.
    Reilly PC Jr, Reilly MC: Costs in Veterans Administration hospitals. Ann Intern Med 93:783, 1980Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1981

Authors and Affiliations

  • Joel I. Hamburger

There are no affiliations available

Personalised recommendations